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Introduction
Guidelines for diagnosis and treatment
of gastroesophageal reflux disease (GERD) were
published by the American College of Gastro-
enterology (ACG) in 1995 and updated in 1999. Two
years later another document was printed, signed by
the Society of American Gastrointestinal and
Endoscopic Surgeons (SAGES). This document
defined indications for surgical treatment of GERD.
Until now, there have been no clear criteria
delineated by indigenous authors, especially in
the specialty of gastroenterological surgery. Existent
guidelines by the Polish Gastroenterological Society
from 2005 do not fully cover surgical treatment
issues.
Already in 1919 A. L. Soresi had written: “The
possibility of gastroesophageal reflux disease
remains an object of interest of both the gastro-
enterologist and the surgeon; however, when
the diagnosis is established, the patient belongs to
the surgeon”. This discordance in surgeons’ and
gastroenterologists’ attitude to GERD demands new
guidelines.
Gastroesophageal reflux disease definition
A new definition of GERD was established in
the last decade. Jamieson and Duranceau’s definition
presumed both physiological and pathological reflux
– the latter called reflux disease, with or without
morphological changes in oesophageal mucosa
(Figure 1). In 2006 at the Montreal conference an
evidence-based definition of GERD was established.
The global consensus on GERD definition aimed at
simplification of the diagnostic and therapeutic
process, scientific cooperation, and giving a chance
for comparative studies for the benefit of patients,
doctors, national health organizations and world
insurance companies.
Finally GERD was defined as: “a chronic condition
in which gastric content is regurgitated into
the oesophagus and causes bothersome symptoms
and/or complications” (Figure 2).
Diagnosis of reflux disease
After analysis of the literature and available
meta-analyses of numerous clinical trials, the fol-
lowing rules in assessment of each patient with
suspected GERD seem justified:
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Figure 1. Classification of reflux disease
according to Jamieson and Duranceau. Jamieson,
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1) taking of detailed medical history,
2) physical examination,
3) additional diagnostic tests.
After detailed anamnesis, a further diagnostic
and therapeutic plan can be devised. It can be
simplified into a few points:
1) reflux disease as a cause of subjective discomfort,
2) cause of reflux disease in a specific patient,
3) consequences of pathological gastroesophageal
reflux,
4) identification of patients at risk of complications
typical for GERD,
5) identification of patients at risk of respiratory
complications in the course of GERD,
6) risk factors affecting final result of treatment,
7) identification and qualification of patients for
optimal (conservative or surgical) treatment
modality.
Diagnostic guideline I: empirical therapy
• Initiation of treatment with proton pump inhibitor
(PPI) at therapeutic dose.
• If symptoms are still present, further diagnostic
steps should be done.
When typical symptoms of reflux disease are
present (heartburn, regurgitation or both), often
immediately after a large, fatty meal, and no risk
of disease complications or Barrett’s oesophagus is
suspected, pharmacological treatment can be
attempted. A positive response with resolution
of symptoms can be confirmative of such symptom
origin. Combination of symptoms with endoscopic
findings is highly specific for GERD (97%). Endoscopy
should be recommended prior to empirical therapy
only when disease complications are suspected or
when both patient and doctor believe it ought to be
done. Further studies should be considered if there is
no response to empirical therapy. 
Likelihood of GERD complications is higher when
alarm symptoms (dysphagia, no effect of empirical
therapy) are present. 
Diagnostic guideline II: endoscopic
examination
Endoscopic examination – necessary:
• diagnostic endoscopy with biopsies for histology
whenever inflammatory changes are present;
• determination of the stage of the disease according




• whenever a diagnosis of Barrett’s oesophagus is
made, the patient is referred to the National
Definition and classification of GERD
Figure 2. Reflux disease classification. The overall definition of GERD, and its constituent syndromes



























• idiopathic lung fibrosis
• recurrent otitis media
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Barrett’s Oesophagus Registry; treatment
of Barrett’s oesophagus is another issue.
Endoscopy is a technology which allows for
thorough examination of the oesophagus and
identification of patients with GERD or Barrett’s
oesophagus. To confirm Barrett’s oesophagus, biopsy
or brush cytology is a must. This test provides
assessment of the magnitude of inflammatory
changes in mucosal lesions. When substantial
inflammation is present and Barrett’s epithelium is
suspected, biopsies should be done after initial
pharmacological treatment to make sure severe
inflammation will not be taken for dysplasia on
microscopic evaluation. 
Broad spectrum of macroscopic changes in reflux
disease is an indication for application of clas-
sifications and grading systems of disease progres-
sion. This simplifies assessment when the patient
changes the centre and allows the course of the
disease to be followed. Los Angeles classification is
most often recommended in oesophagitis. The next
most popular one is the Savary-Miller scale in original
or modified version (Table I). MUSE classification is
less common. So-called alarming symptoms (body
weight reduction, GI bleeding, dysphagia),
substantial symptom intensity and ineffectiveness
of pharmacological therapy are particular indications
for endoscopy. For assessment of metaplasia, Prague
C&M classification is applied most often. To properly
assess metaplasia, certain conditions must be met:
• skill of endoscopic diagnosis of metaplasia,
• ability to identify squamocolumnar junction (Z line)
on endoscopy,
• ability to identify high pressure zone (diaphra-
gmatic impression/hhe) on endoscopy,
• endoscopic definition of C (circumferential) area
and M (maximum) protrusion of glandular
epithelium into the oesophagus, for instance C2, M5.
However, biopsy remains the basis for micro-
scopic verification.
Diagnostic guideline III: radiological studies
Radiological examination – indicated – with double
contrast:
• assessment of the size and type of hiatal
diaphragmatic hernia,
• initial judgement of oesophageal contractility
(limited availability of oesophageal manometry in
Poland),
• shortened oesophagus diagnosis – qualification for
Collis gastroplasty.
Double contrast examination in its active phase
provides valuable information when endoscopy cannot
be done. It allows one to assess morphology
of the oesophagus, strictures, and the size of large
diaphragmatic hernias. It is also a valuable indication for
a surgeon planning surgical treatment in the future.
Reduction of the hernia in upright position gives a better
chance for a tension-free procedure with no need for
Los Angeles Savary-Miller Modified Savary-Miller
A: at least one mucosa lesion I: one or more non-confluent mucosal I: single erosive or exudative lesion,
< 5 mm long lesions with erythema or exudate oval or linear, taking only one
B: at least one mucosa lesion or superficial erosion longitudinal fold
> 5 mm long, not affecting whole II: erosive or exudative mucosal II: noncircular multiple erosions or
area between two neighbouring lesions confluent without covering exudative lesions taking more than
oesophageal mucosal folds the entire circumference of the one longitudinal fold, with or
C: at least one lesion of mucosa oesophagus without confluence
affecting whole area between two III: erosive and exudative lesions III: circular erosive or exudative lesion
or more oesophageal mucosal folds, cover the whole oesophageal mucus IV: chronic lesions: ulcer(s), stricture(s),
and less than 75% of oesophagus membrane circumferentially and lead or short oesophagus, isolated or
circumference to inflammatory infiltration of the associated with lesions of grades I, II, or III
D: lesion of mucosa affecting at wall without stricture V: islands, finger-like forms or
least 75% of circumference of the IV: appearance of chronic mucosal circumferential distribution of Barrett’s
oesophagus lesions (ulcer, fibrosis of the wall, epithelium isolated or associated with
stricture, short oesophagus, scarring lesions of grades I to IV
with columnar epithelium)
Table I. Classifications of oesophagitis: Los Angeles, Savary-Miller and modified Savary-Miller
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Collins gastroplasty when shortening of the oesophagus
is present. Spontaneous contrast regurgitation in
upright position is a pathognomonic sign.
Diagnostic guideline IV:
pH-metry/multi-channel gastroesophageal
impedance with pH monitoring
pH-metry/multi-channel intraluminal gastroeso-
phageal impedance and pH monitoring is indicated in:
• unsure diagnosis and qualification for surgery,
• presence of clinical symptoms of reflux disease
without endoscopic lesions,
• need for diagnosis of non-acidic or mixed type reflux,
• presence of extra-oesophageal symptoms,
• control of conservative or operative treatment.
To confirm a chain of cause-and-effect relationship
of inflammatory changes in the oesophagus, studies
monitoring reflux of gastric content into the
oesophagus are indicated, especially when surgery is
planned. Many patients with documented acidic
gastric content regurgitation do not present with
oesophagitis. On the other hand, there are patients
with significant lesions or pronounced symptoms
without any proof of acidic regurgitation. Adequately
treated patients with persistent symptoms fall into
the latter group. These patients finally are candidates
for multi-channel intraluminal impedance and pH
monitoring. This test allows for physical deter-
mination of the number of reflux episodes per day
and assessment of regurgitated gastric content
acidity. This test also affords control of treatment
results and can be performed during therapy with PPI
or histamine H2 receptor inhibitors.
Diagnostic guideline V: oesophageal
manometry
Oesophageal manometry – test recommended in
dysphagia, when aforementioned studies have been
completed:
• assessment of motor activity of the oesophagus
and lower oesophageal sphincter (LES),
• confirmation or exclusion of primary oesophageal
motor activity changes,
• diagnosis of achalasia, diffuse oesophageal spasm
(DES) or nutcracker oesophagus.
Allows for precise pH-metric sensor placement 
(5 cm above upper margin of lower oesophageal
sphincter), documents normal or aberrant peristalsis
of the oesophagus and function of oesophageal
sphincters. Propulsive function of the lower part
of the oesophagus, length of its abdominal part and
resting pressure of the lower oesophageal sphincter
are all important information to a surgeon. Only
these basic parameters give a chance for planning
anti-reflux surgery. At present, high resolution
manometry with intraluminal oesophageal impe-
dance measurement is becoming more and more
popular in pre-operative patient workup.
Gastroesophageal reflux disease
pharmacotherapy
Detailed guidelines of pharmacotherapy were
prepared and presented by the Working Group
of the Polish Society of Gastroenterology (2005).
A basis for any treatment is patients’ will to
cooperate. In many patients with GERD a decrease in
magnitude of symptoms can be achieved with
change of diet and lifestyle with small doses
of anti-secretory agents. At the moment, PPI are
recommended in two dosing schemes.
In the first regimen, therapy is begun with a single
dose (10-20 mg) administered 20 min before
breakfast. When there is no improvement, the single
dose is doubled (20-40 mg), and when the problem
persists, twice-daily dosage is introduced up to 80 mg
per day in two fractionated doses. Administration
of H2-inhibitor monotherapy is not recommended, as
their efficacy is lower than PPI. In reasonable cases an
additional night dose can be administered, reducing
so-called nocturnal acidic regurgitation.
In the second regimen therapy is begun with high
doses of PPI, which are reduced later to a dosage
which allows for control of symptoms in a particular
patient. It should be stressed that treatment ought to
be tailored to each individual patient. Such regimens
are described as step up and step down strategies. If
surgical treatment is considered, and a patient has
pronounced inflammatory lesions, pharmacotherapy
is recommended as a first, safer choice with
subsequent anti-reflux surgery. 
Prokinetic agents, as aetiopathogenetically most
reasonable, are not recommended either in GERD
monotherapy or in combination with hyposecretory
treatment. Commencing intensive treatment with
high-dose PPI in patients with symptoms from
the respiratory system potentially resulting from
unconfirmed GERD should not be practised.
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Surgical treatment
Indications for surgery concern only patients with
well-documented reflux disease who:
1) did not improve in spite of intensive pharma-
cological therapy,
2) choose surgical treatment despite adequate
pharmacological treatment, are young, have to
constantly adhere to medical therapy even for
the rest of their lives, which involves high
expenses, or whose lifestyle excludes regular
treatment,
3) develop reflux disease complications (Barrett’s
oesophagus, high grade oesophagitis),
4) have accompanying large hiatal hernia with
complications such as bleeding or dysphagia,
5) have atypical symptoms (asthma, hoarse, chest
pain, choking).
Operative treatment should not be considered
only as an efficient alternative to pharmacotherapy,
but should rather be seen as a method aimed at
determining correction of the mechanical cause
of reflux disease, with a satisfactory result achieved
in 85-93% of patients. Guidelines for patient
qualification for anti-reflux surgery, accepted by
the American Society of Gastroenterology, are as
follows:
• no effect of pharmacotherapy,
• patients requiring increasing dosage of therapy,
with disease progression,
• no effect of maintenance therapy – development
of complications (shortening of oesophagus,
ulceration, motor impairment) despite pharmaco-
therapy,
• young patients, requiring long-term aggressive
therapy,
• patient non-adherence, costs, fear of drug side
effects,
• refusal of chronic pharmacotherapy,
• patients with stage 3-4 reflux oesophagitis with
high risk of complications – mostly with non-acidic
and mixed reflux,
• patients with low grade dysplasia, with efficient LES,
• patients with large sliding hiatus hernia resistant to
pharmacological treatment,
• complicated reflux disease – strictures, ulcerations,
Barrett’s oesophagus,
• pulmonary complications – aspiration, repeated
pneumonias, chronic laryngitis, and other extra-
oesophageal symptoms.
When planning surgical treatment in reflux
disease so-called absolute indications for operative
treatment should also be considered:
• perforation of:
– Barrett’s ulcer,
– gastic peptic ulcer within the thorax,
– iatrogenic (instrumental);
• uncontrolled bleeding from GI tract:
– Barrett’s ulcer,
– peptic ulcer of the stomach within the thorax;
• signs of bowel obstruction:
– organic stricture type,
– advanced peptic stricture;
• necrosis of the stomach:
– organic stricture with signs of strangulation;
• aspiration to respiratory system resistant to
therapy:
– recurrent laryngitis or tracheitis,
– recurrent bronchitis;
• signs of malignancy:
– confirmed or suspected malignancy in Barrett’s
oesophagus.
Special attention must be paid to patients with
Barrett’s oesophagus due to the risk of adeno-
carcinoma development. Resection of the oeso-
phagus ought to be considered if the patient presents
with extensive lesions and high-grade dysplasia.
The goal of the surgical anti-reflux procedure is to
stop gastric content regurgitation. Its superiority over
pharmacotherapy has been proven in numerous
controlled clinical studies. Anti-reflux surgery
efficiently corrects a mechanically deficient existing
valve and prevents temporary loss of sphincter
function occurring at distension of the stomach.
Years-long studies have shown such correction to
alleviate heartburn and regurgitation symptoms, cure
oesophagitis, inhibit disease progression and be
effective 10 years after surgery. The efficacy of surgical
treatment depends on the experience of the surgeon
and adequate preoperative patient assessment.
Goals of surgical treatment are as follows:
1) obtain appropriate length of the abdominal part
of the oesophagus from its mobilization to secure
tension-free fundoplication, which would stay
below the diaphragm,
2) prepare and mobilize the gastric fundus widely
enough to make sure that the formed cuff would
not rotate in the longitudinal axis and decrease
the tension of fundoplication,
3) reduce diaphragmatic hiatus opening.
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The gold standard for treatment of reflux disease
is now laparoscopic fundoplication. This method has
brought about a significant reduction of hospita-
lization and patient convalescence time. Full Nissen’s
or Nissen-Rosetti’s fundoplication is recommended in
patients with normal oesophageal motor function. In
patients with significant dysfunction, non-complete
posterior Toupet’s fundoplication should be
considered. Descriptions of anti-reflux procedures are
widely available in the literature and identical for
both open and laparoscopic access. Choice
of technique depends on the surgeon’s preferences
and practicality; numerous modifications of the
mentioned methods can be seen.
In some cases, such as coexistent chest pathology,
or grade 3 or 4 incarcerated diaphragmatic hiatus
hernia, the procedure can be completed through
thoracotomy, yet it is not recommended access.
When short oesophagus is found or when there is
significant tension after reducing reconstructed
cardia into the abdominal cavity, the Collis procedure
with fundoplication ought to be done.
Endoscopic treatment
As a method with expected high efficacy and low
complication rate, endoscopic treatment is gaining
increasing popularity and is a subject of meticulous
assessment of clinical efficiency. At the moment, only
two methods are accepted by FDA: Stretta and
EsophyX™. Recommendations for biopolymers have
been withdrawn due to the substantial complication
rate. EsophyX™ is a minimally invasive method
of reflux disease treatment, and has recently been
approved in the European Union for endoscopic
fundoplication. The Stretta method uses radio-
frequency energy on the LES and the subcardial area.
This results in an increase of LES tension and
muscular layer hypertrophy and decreases the
number of transient sphincter relaxations. It is
the only method with efficacy confirmed with
randomized studies. Radiofrequency is also used for
Barrett’s epithelium ablation with Halo 360 and
Halo 90 apparatus. More traditional measures, such
as endoscopic mucosectomy, argon or laser ablation,
have been used for a much longer time. Any
procedure of Barrett’s epithelium removal ought to
be supplemented with surgical or endoscopic
fundoplication.
Summary
Reflux disease is a serious problem of not only
medical, but also economic significance. The costs
of long-term pharmacological treatment are
tremendous. Surgical treatment for the majority
of these patients seems justified. Such therapy ought
to be undertaken in a centre with the volume
exceeding 50 anti-reflux procedures per year. The
procedure performed by an experienced surgeon
gives a chance for remission of symptoms for over
5 years in more than 90% of patients. Application
of laparoscopic techniques has made this method
of treatment much more attractive.
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